Literature DB >> 10856794

Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity.

D J Marciani1, J B Press, R C Reynolds, A K Pathak, V Pathak, L E Gundy, J T Farmer, M S Koratich, R D May.   

Abstract

Aldehyde-containing triterpene saponins have adjuvant properties, but only those from Quillaja saponaria Molina stimulate the production of cytotoxic T lymphocytes (CTL) against exogenous antigens. Quillaja saponins have two normonoterpene ester moieties, linked linearly to their fucosyl residue, that play a critical role in the stimulation of CTL. These ester moieties are also responsible for these saponins' instability and toxicity. Based on the structure-activity relationships for the different groups of Q. saponaria saponins, new semi-synthetic analogs were developed that have the adjuvanticity of quillaja saponins, yet with less toxicity and greater stability in aqueous solutions. The quillaja saponin analogs were prepared by replacing their hydrolytically unstable ester groups with another lipophilic chain linked by a stable amide bond on these saponins' glucuronic acid residue. One of these analogs, GPI-0100, is a dodecylamide saponin derivative that stimulates an antibody isotype profile that corresponds to a Th1 type immune response, as well as CTL production against exogenous antigens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10856794     DOI: 10.1016/s0264-410x(00)00118-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

Authors:  Govind Ragupathi; Payal Damani; Kai Deng; Michelle M Adams; Jianfeng Hang; Constantine George; Philip O Livingston; David Y Gin
Journal:  Vaccine       Date:  2010-05-05       Impact factor: 3.641

2.  Immunomodulatory and anticancer effects of Pituranthos tortuosus essential oil.

Authors:  Mounira Krifa; Hala El Mekdad; Nawel Bentouati; Antonio Pizzi; Kamel Ghedira; Mohamed Hammami; Salah Edin El Meshri; Leila Chekir-Ghedira
Journal:  Tumour Biol       Date:  2015-02-08

3.  TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B.

Authors:  Dalia E Gaddis; Suzanne M Michalek; Jannet Katz
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

4.  Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Authors:  Kai Deng; Michelle M Adams; Payal Damani; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

Review 5.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

6.  Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Authors:  Heng Liu; Jacqueline de Vries-Idema; Wouter Ter Veer; Jan Wilschut; Anke Huckriede
Journal:  Med Microbiol Immunol       Date:  2013-09-24       Impact factor: 3.402

7.  A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma.

Authors:  Xiaoping Zhang; Neng-Lian Li; Chao Guo; Ying-Dong Li; Lu-Lu Luo; Yong-Qi Liu; Yun-Yan Duan; Zhen-Dong Li; Xiao-Rong Xie; Hai-Xia Song; Li-Ping Yang; Fang-Yu An
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

8.  Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.

Authors:  Pengfei Wang; Đani Škalamera; Xianwei Sui; Ping Zhang; Suzanne M Michalek
Journal:  ACS Infect Dis       Date:  2019-03-28       Impact factor: 5.084

9.  Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.

Authors:  Balasubramanyam Karanam; Ratish Gambhira; Shiwen Peng; Subhashini Jagu; Dae-Jin Kim; Gary W Ketner; Peter L Stern; Robert J Adams; Richard B S Roden
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641

10.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.